Genus plc · Valuation · TradingHolo

Genus plc · Valuation · TradingHolo

Multiples

Shown only where the company is comparable with its peers

Multiple	Now	Sector median	Where it sits
P/E	5.3×	−0.3×
Price / Book	2.0×	2.6×
Price / Sales	2.3×	3.5×
Price / Free cash flow	19.2×	4.2×
EV / EBITDA	12.2×	6.8×
Earnings yield	19.0%	−0.7%
Free cash flow yield	5.2%	0.6%

P/E at each quarterly report

Price at the report date ÷ trailing twelve-month earnings

No comparable valuation history is available.

Peers

Same market and sector · market cap in USD

Company	Price	Change	Mkt cap (USD)	P/E	ROE	1Y
LSE:0QCV.LAbbVie Inc. · 🌐 LSE	—	—	—	111.2×	−129.2%	—
LSE:0QAH.LMerck & Co., Inc. · 🌐 LSE	—	—	—	20.5×	34.7%	—
LSE:0QQ6.LRoche Holding AG · 🌐 LSE	—	—	—	23.2×	38.1%	—
LSE:AZN.LAstraZeneca PLC · 🌐 LSE	£125.38	+1.11%	$259.85B	25.1×	21.0%	−1.3%
LSE:0R0H.LThermo Fisher Scientific Inc. · 🌐 LSE	—	—	—	34.0×	12.6%	—
LSE:0R2B.LDanaher Corporation · 🌐 LSE	—	—	—	41.6×	6.9%	—
LSE:0R29.LIntuitive Surgical, Inc. · 🌐 LSE	—	—	—	50.4×	16.0%	—
LSE:0QZU.LVertex Pharmaceuticals Incorporated · 🌐 LSE	—	—	—	35.5×	21.2%	—
LSE:0R1F.LBristol-Myers Squibb Company · 🌐 LSE	—	—	—	16.5×	27.3%	—
LSE:0R2S.LStryker Corporation · 🌐 LSE	—	—	—	40.6×	14.5%	—